Figure 2.

One‐micrometer thick toluidine blue‐stained representative cross sections of sciatic nerves (a) from control Tr^J mice (injected with PBS), treated with pyruvate (PYR) and pyruvate plus AAV1.NT‐3 gene therapy (PYR + NT‐3) at 16 weeks. Thinly myelinated and naked axons are indicated with arrows in PBS‐treated nerves. PYR alone and combinatorial therapy result in an increase of axons with thicker myelin and an apparent increase in the small myelinated fibers. Composite histograms showing myelinated fiber distribution in the sciatic nerves (b) from control Tr^J mice (PBS), treated with PYR and PYR + NT‐3 at 16 weeks showing an increase in the subpopulation of axons <4 μm in diameter in the PYR and PYR + NT‐3 treatment groups compared to PBS‐control. G ratio distribution of fibers in the sciatic nerves from Tr^J mice treated with PBS, PYR, or PYR + NT‐3 for 16 weeks (c). A shift toward increased percent of fibers with smaller G ratio (thicker myelin) is more pronounced with the combination treatment